The gln27 beta adrenoceptor polymorphism is associated with bronchodilator reversibility in subjects with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 96s Year: 2002
The role of β-2 adrenoceptor desensitization on physical performance at the high altitude and association of resistance of adrenoceptors to desensitization with gene polymorphism Source: Eur Respir J 2001; 18: Suppl. 33, 1s Year: 2001
The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Use of multifactor-dimensionality reduction model predicting bronchodilator response by inhaled short-acting beta 2 agonist Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
A potential role for dissociation rate from the M3 muscarinic receptor in the onset of action of NVA237 and tiotropium Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Use of partition tree to Identify genetic marker combination predicting bronchodilator response by inhaled short-acting beta 2 agonist Source: Annual Congress 2011 - Genetics of airway diseases and treatment Year: 2011
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
The efficacy and safety of long-acting muscarinic antagonist treatment for COPD Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma Year: 2019
Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007
The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
The effect of topical ophthalmic timolol in patients treated for COPD with inhaled beta adrenergic agonist albuterol Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006
Will a cumulative dose reversibility test increase the power in a dose-response study comparing formoterol and terbutaline? Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Arg16Gly polymorphism of the β2 -adrenergic receptor gene does not modulate clinical response to salmeterol in subjects with asthmaSource: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment Year: 2008
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007
A randomised, double-blind study to determine the duration of action of lung pharmacodynamics by plethysmography (sGaw) of a b2 adrenoreceptor agonist, PF-00610355 Source: Annual Congress 2009 - New bronchodilators Year: 2009